Eradication of HCV in Renal Transplant Recipients and Its Effects on Quality of Life

Table 1

Patient characteristics at baseline (n=16).

Demographic characteristics
Age, y	64 (26-71)
Sex (M/F)	11/5
Time from RTX to HCV therapy, mo	150.9 (84.4)
Cause of end-stage renal disease
Vesicoureteral reflux	1
Chronic glomerulonephritis	6
Others or unknown	9
HCV genotype:
1a	1
1b	10
2	4
4	1
Baseline laboratory values
Creatinine, mg/dL	1.29 (0.80-1.80)
eGFR, mL/min/1.73 m^2	60.3 (19.3)
Proteinuria (g/24 hours)	0.582 (0,768)
Bilirubin: total, mg/dL	0.58 (0.50-0.80)
GGT, U/L	47.5 (16-306)
ALT, U/L	30.2 (11 -137)
AST, U/L	31.4 (17 -85)
ALP, U/L	95.1 (41.3)
Total serum protein, g/dL	6.91 (0.50)
Albumin, g/dL	4.15 (0.37)
AFP, IU/mL	2.93 (2.62)
Hemoglobin, g/dL	12.87 (1.13)
WBC count, /μL	7.40 (1.57)
Platelet count, /μL	218.43 (62.16)
FibroScan value (kPa)	9.31 (1.75)
Viral load (log10 IU/mL)	2.1E (4.1E-1.3E)

Data are expressed as median (range) or mean (standard deviation). Abbreviations. eGFR: estimated glomerular filtration rate; GGT: γ-glutamyl-transpeptidase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; AFP: alpha fetoprotein (0-4 IU/ml).